coteauBeta Get App

VTRS

Viatris Inc.
$18.65
+2.14% Oct 20 close
Health CareS&P 500 Compare
1M3M6M1Y2Y
-5%+18%+41%+64%+87%Oct 2025Oct 2026Apr 2026
VTRSSPY
1W
+8.1%
1M
+10.0%
3M
+6.8%
6M
+28.5%
YTD
+53.3%
1Y
+87.3%

Live chart

Loading live chart…

What they do

Viatris Inc. operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.

Healthcare · Drug Manufacturers - Specialty & Generic

For information only · Important disclosures

Grades vs sector

Momentum
90th percentile in sector
A
12-1 return: +77.1%
Percentile within its GICS sector across the S&P 1500.
Growth
26th percentile in sector
D+
Revenue growth (YoY): +4.9%
Percentile within its GICS sector across the S&P 1500.
Value
93rd percentile in sector
A
Forward E/P: 14.4% · EBITDA/EV: 12.8%
Percentile within its GICS sector across the S&P 1500.
Profitability
19th percentile in sector
D
Profit margin: -2.8% · Return on equity: -2.8%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 41 of 499 · 12-month momentum 72.7%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
Stocktwits · Oct 12

Key stats

Market value$21.4B
P/E (next 12 months, estimated)7.0
52-week range$9.92 – $18.75
Revenue growth (latest quarter vs a year ago)+4.9%
Dividend yield2.63%
Analyst consensusBuy (10)
Average analyst price target$19.70 (+6%)
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Looks expensive
Model read-out from the numbers below, not advice. Score -3 (DCF counts double).
▼DCF (base case)below the price by 21%
▲Forward P/E vs sector7.0x vs median 17.6x
▼Altman Z1.1 (distress)
▼Net debt / EBITDA4.6x
•Analyst target+6% (10 analysts)

Discounted cash flow

Bear
$5
-73%
growth -5% · disc. 9.5% · term. 2.0%
Base
$15
-21%
growth 0% · disc. 8.5% · term. 2.5%
Bull
$29
+53%
growth 3% · disc. 7.5% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows about 3% a year for 10 years.
Implied
+3%/yr
FCF, last 3 yrs
-9%/yr
FCF, last 5 yrs
+14%/yr
Revenue, last 3 yrs
-4%/yr
Revenue, last 5 yrs
+4%/yr
Same inputs as the DCF above: trailing free cash flow 2.0B, 8.5% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.86 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 29.9×
 –
Forward P/E
sector median 17.6× · 5th pct
 7.0×
cheaper
EV / EBITDA
sector median 15.8× · 29th pct
 12.5×
cheaper
Price / sales
sector median 3.1× · 24th pct
 1.5×
cheaper
Price / book
sector median 3.5×
 –
FCF yield
sector median 4.1% · 87th pct
 9.1%
cheaper

Forward EPS $2.68 vs trailing $-0.36. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
34.8%
Operating margin
-0.6%
FCF margin
13.3%
Net margin
–
Return on equity
–
Return on invested capital
-0.6%
Net debt / EBITDA
4.6×
Current ratio
1.6×
Interest cover
-0.2×
Cash conversion (OCF/NI)
–

Altman Z-score 1.1 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$20
+6%
Analysts
10
Buy
Range
$13–$26
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$14.3B–$1.9B
2024$14.7B–$2.0B
2023$15.4B–$2.5B
2022$16.3B–$2.6B
2021$17.9B–$2.6B
2020$11.9B–$988.8M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -4.2%.

Earnings

Next report: 2026-11-05 · before open · EPS est 0.64
24-1125-0225-0525-0825-1126-0226-0526-080.000.75
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-08-060.600.69+15.0%
2026-05-070.500.59+17.5%
2026-02-260.530.57+7.4%
2025-11-060.620.67+8.5%
2025-08-070.560.62+11.6%
2025-05-080.490.50+1.6%
2025-02-270.570.54-5.6%
2024-11-070.680.75+10.7%
Insider trades
None
None · None
SELL
–
None
None · None
SELL
–
None
None · None
SELL
–

Stats refreshed 2026-10-21 18:05:24 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

How it worksDisclaimerTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026